Neurocrine Biosciences | NBIX - Pre Tax Profit

Stock Price
141.25
Daily Change
3.32 2.41%
Monthly
0.45%
Yearly
15.19%
Q1 Forecast
131.87

Neurocrine Biosciences reported $291.8M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Acadia Pharmaceuticals USD 44.6M 4.38M Sep/2025
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
ALKERMES USD 100.74M 4.1M Sep/2025
Alnylam Pharmaceuticals USD 238.97M 274.33M Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
Biogen USD 557.3M 186.7M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Cytokinetics USD -306.18M 171.81M Sep/2025
Dynavax Technologies USD 28.42M 7.2M Sep/2025
Exelixis USD 252.41M 22M Sep/2025
Gilead Sciences USD 2.43B 780M Jun/2025
Halozyme Therapeutics USD 218.96M 14.02M Sep/2025
Incyte USD 482.31M 75.7M Sep/2025
Ionis Pharmaceuticals USD -129M 253M Sep/2025
Neurocrine Biosciences USD 291.8M 132.3M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
Prothena USD -36.91M 44.05M Sep/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Repligen USD 17.11M 10.25M Sep/2025
Sarepta Therapeutics USD -194.05M 347.69M Sep/2025
Teva Pharmaceutical Industries USD 91M 555M Dec/2025
Ultragenyx Pharmaceutical USD -179.54M 65.54M Sep/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025